NCT04591717View on ClinicalTrials.gov

COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

April 20, 2022

Study Completion Date

January 18, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

hAd5-S-Fusion+N-ETSD vaccine

The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

Trial Locations (2)

90245

Chan Soon - Shiong Institute for Medicine, El Segundo

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY